TEM

Tempus AI (TEM) is strengthening its precision medicine presence through multiple strategic collaborations, including support for Moderna and Merck's cancer therapy commercialization and an extended data partnership with Recursion Pharmaceuticals through 2029. However, TEM's stock has underperformed the industry by 30.6% over the past year and trades at a premium valuation of 6.73X forward P/S versus the industry average of 4.90X, with the stock currently rated a Hold.

Tempus AI (TEM) shares gained 17.9% over the past month, outperforming peers like Claritev and iRhythm, driven by strong demand for healthcare AI. The company reported 28% revenue growth in its Data and Applications segment to $93.2M in Q2, with Insights revenues up 36%.

However, TEM trades at a premium valuation of 6.59X sales versus the industry average of 4.70X, and its growth depends heavily on regulatory approvals and reimbursement decisions. Analysts recommend current holders maintain positions while prospective investors wait for a more favorable entry point.